In-licensing and monotherapy development of NS-917 (DFP-10917)
An individual development theme for NS-917 (DFP-10917), licensed in from Delta-Fly Pharma, involving the continuation of a post-licensing Phase I clinical trial in patients with relapsed or refractory acute myeloid leukemia.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.